RTP Mobile Logo
Dissecting the Decision: Investigators Discuss PARP Inhibition in the Management of Ovarian Cancer
Released June 2017

Proceedings from an independent satellite symposium during the Society of Gynecologic Oncology’s 2017 Annual Meeting on Women’s Cancer. Featuring perspectives from Drs Robert L Coleman, Jonathan A Ledermann, Ursula A Matulonis and Richard T Penson. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.

    The American Cancer Society estimates that in 2017, 22,440 new cases of ovarian cancer (OC) will be diagnosed in the United States and 14,080 individuals will die of the disease. For this reason significant financial and intellectual resources have been invested over the past few decades in attempts to better understand the natural history of the disease, identify genetic and other factors responsible for its proliferation and develop novel therapies with the potential to significantly improve outcomes for patients, ultimately culminating in — among other things — a number of clinical trials attempting to document the efficacy of various PARP inhibitors across multiple rational OC populations. Given the significant number of clinical and research questions created by the introduction of PARP inhibitors in the OC treatment milieu and the rapidly expanding database surrounding PARP inhibition in general, clinicians must be aware of emerging data and available protocols so that they may effectively counsel their patients.

    These video proceedings from a CME symposium held during the Society of Gynecologic Oncology’s 2017 Annual Meeting on Women’s Cancer feature discussions with leading researchers with an expertise in gynecologic oncology. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers with the formulation of up-to-date clinical management strategies for OC.


    • Consider available guidelines and consensus statements in the development of evidence-based approaches to genetic screening for patients with OC.
    • Examine clinical investigator perspectives to assist healthcare professionals in the selection of a validated genetic testing platform(s) for patients with OC, and use the results from these assessments to guide treatment planning.
    • Appraise the efficacy and safety of approved and investigational PARP inhibitors as monotherapy for patients with BRCA-mutant advanced OC, and employ this information in the formulation of protocol and nonprotocol treatment recommendations for these individuals.
    • Evaluate emerging Phase III evidence supporting the potential use of PARP inhibition as maintenance therapy for patients with recurrent, platinum-sensitive OC.
    • Educate patients about the potential side effects associated with approved and investigational PARP inhibitors, and provide preventive and emergent strategies to reduce or ameliorate these toxicities.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Robert L Coleman, MD
    Professor and Deputy Chairman
    Vice Chair, Clinical Research
    Ann Rife Cox Chair in Gynecology
    Department of Gynecologic Oncology and Reproductive Medicine
    The University of Texas
    MD Anderson Cancer Center
    Houston, Texas

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Cerulean Pharma Inc, Clovis Onocology, Eisai Inc, GamaMabs Pharma, Genentech BioOncology, Incyte Corporation, Janssen Biotech Inc, Merck, Novocure, Pfizer Inc, Roche Laboratories Inc, Vertex Pharmaceuticals Incorporated; Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Debiopharm Group, Genmab, ImmunoGen Inc, Merck, Merrimack Pharmaceuticals Inc, Perthera, Takeda Oncology, Verastem Inc; Contracted Research: Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, EMD Serono Inc, Gradalis Inc, Janssen Biotech Inc, Merck; Speakers Bureau: AstraZeneca Pharmaceuticals LP, CancerNet, Roche Laboratories Inc.

    Jonathan A Ledermann, MD
    Professor of Medical Oncology
    University College London (UCL)
    Cancer Institute
    Clinical Director, UCL Cancer Institute
    Director, The Cancer Research UK and UCL Cancer Trials Centre
    London, United Kingdom

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Merck, Pfizer Inc, Roche Laboratories Inc; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Pfizer Inc.

    Ursula A Matulonis, MD
    Medical Director and Program Leader
    Gynecologic Oncology Program
    Associate Professor of Medicine
    Harvard Medical School
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Cerulean Pharma Inc, Clovis Oncology, Genentech BioOncology, ImmunoGen Inc, Lilly; Consulting Agreement: AstraZeneca Pharmaceuticals LP.

    Richard T Penson, MD, MRCP
    Associate Professor of Medicine
    Harvard Medical School
    Clinical Director, Medical Oncology
    Massachusetts General Hospital
    Boston, Massachusetts

    Advisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Clovis Oncology, Genentech BioOncology, Roche Laboratories Inc, Vascular Biogenics; Consulting Agreement: Schulman IRB; Contracted Research: AstraZeneca Pharmaceuticals LP, Eisai Inc, Genentech BioOncology, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly, Roche Laboratories Inc, Vascular Biogenics; Data and Safety Monitoring Board: AbbVie Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

    This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Myriad Genetic Laboratories Inc and Tesaro Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: June 2017
    Expiration date: June 2018

Acknowledge and close

Watch video
(WIFI is recommended for best performance):